Clinical trials: Malaria, completed
Malaria in Pregnancy
New Approaches to Improve Coverage and Compliance of Antimalarial Treatment for Pregnant Women in Rural Africa
Malaria in pregnancy contributes substantially to maternal anaemia and low birth weight: effective malaria control in pregnancy could avoid about 10,000 maternal and up to 200,000 infant deaths every year.
- Trial name
- NCT00730366
- Testing
- sulfadoxine-pyrimethamine, Chloroquine
- Where
- Burkina Faso
- Volunteers
- 2,766 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Malaria,Falciparum, Malaria
CHILD (Child Health and Infection With Low Density) Malaria
This trial will assess the long-term health and socioeconomic impact of interventions targeting low-density malaria infection (LMI) among children in Tanzania
- Trial name
- NCT05567016
- Testing
- Active case detection using molecular testing (ACDm), Passive case detection using molecular testing (PCDm), Control (standard of care)
- Where
- Tanzania
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Malaria
Efficacy of Only IV Artesunate Versus IV Artesunate Plus IV Quinine in the Treatment of Severe Malaria in Children: A Comparative Study
The WHO recommends artesunate as the drug of choice for the treatment of severe malaria. However, the efficacy of this single drug as compared to the combined drug regimen remained questionable, and the clinical response was…
- Trial name
- NCT06472258
- Testing
- IV Artesunate, IV Quinine Hydrochloride
- Where
- Pakistan
- Volunteers
- 104 people
- Sponsor
- RESnTEC, Institute of Research
Malaria
Safety and Immunogenicity of Malaria Vaccines AdCh63 AMA1, MVA AMA1 and AMA1-C1/Alhydrogel®+/- CPG 7909
This study aims to compare the safety and immunogenicity of AdCh63 AMA1 and MVA AMA1vaccine candidates administered alone and with adjuvants in various schedules.
- Trial name
- NCT01351948
- Testing
- AdCh63 AMA1 + MVA AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909, AdCh63 AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909, AdCh63 AMA1 + AMA1-C1/Alhydrogel®
- Where
- United Kingdom
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
Study to Assess the Vaccine Efficacy Against Malaria Infection, in Children Immunized With the Primary and Yearly Booster of the RTS,S/AS01E Vaccine, as Part of Their Participation in the Malaria-094 (204889/NCT03276962) Study.
The aim of this study was to evaluate the effectiveness of the RTS,S/AS01E malaria vaccine against both clinical and asymptomatic malaria infections by detecting Plasmodium falciparum (P.
- Trial name
- NCT03281291
- Where
- 2 sites in Ghana, Kenya
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Anaemia, Malaria
Schistosome and Intestinal Worm Infections and Malaria Morbidity Among School and Pre-school Children in, Tanzania
The proposed study has as the main objective to investigate the effect of schistosome and STH infections and the effect of an anthelminthic intervention on P.
- Conditions
- Anaemia, Malaria, Hepatosplenomegaly
- Trial name
- NCT00347113
- Testing
- Albendazole and praziquantel
- Where
- Tanzania
- Volunteers
- 620 people
- Sponsor
- DBL -Institute for Health Research and Development
Malaria, Respiratory Tract Infection Acute
Star Homes Project 2
Malaria, pneumonia and diarrhoea causes a lot of illness in children in Tanzania and the study want to find better ways of protecting people against these diseases and want to find out if the type of house design can affect the…
- Conditions
- Malaria, Respiratory Tract Infection Acute, Diarrhoea;Acute
- Trial name
- SHP2 (NCT04529434)
- Testing
- Star Homes, Traditional African houses
- Where
- Tanzania
- Volunteers
- 1,183 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
Plasmodium and Other Parasites in Pregnant Women and Children Around Margibi and Montserrado Counties, Liberia
Background: The disease malaria affects many people in Liberia and other parts of Africa. It is caused by germs that are spread by mosquito bites.
- Trial name
- NCT03719599
- Where
- 2 sites in Liberia
- Volunteers
- 1,264 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Phase I Study of Safety and Immunogenicity of AMA1-C1Alhydrogel + CPG 7909 Vaccine for Malaria
This study will evaluate the safety of an experimental vaccine can protect people from malaria and study its effects. Malaria, which affects many people in Mali and other countries in Africa, is caused by germs spread by mosquito…
- Trial name
- NCT00414336
- Testing
- AMA1-C1/Alhydrogel + CPG 7909 Vaccine
- Where
- Mali
- Volunteers
- 150 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali
Background: Researchers are looking for new ways to control and eradicate malaria. They want to test vaccines to block malaria transmission in adults in Mali. These vaccines work by inducing antibodies in a person.
- Trial name
- NCT02942277
- Testing
- Pfs25M-EPA, Pfs230D1M-EPA, AS01
- Where
- Mali
- Volunteers
- 301 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Vivax
Tafenoquine Thorough QTc Study in Healthy Subjects
This will be a randomized, single-blind, placebo controlled, parallel group study. Approximately 260 subjects will be enrolled in five groups.
- Trial name
- NCT01928914
- Testing
- Tafenoquine 300mg, Tafenoquine 600mg, Tafenoquine 1200mg
- Where
- 2 sites in United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pregnancy Malaria, Bacterial Vaginoses
The ASPIRE Trial - Aiming for Safe Pregnancies by Reducing Malaria and Infections of the Reproductive Tract
Malaria in pregnancy has devastating consequences for mother and foetus. WHO recommends intermittent preventive treatment in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) for asymptomatic women, but high-level parasite…
- Conditions
- Pregnancy Malaria, Bacterial Vaginoses, Trichomonas Vaginitis
- Trial name
- NCT04189744
- Testing
- IPTp-sulphadoxine-pyrimethamine plus metronidazole, IPTp-dihydroartemisinin-piperaquine plus metronidazole, IPTp-sulphadoxine-pyrimethamine
- Where
- Zambia
- Volunteers
- 5,436 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Plasmodium Falciparum Infection
Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of Three or Five Administrations of GAP3KO Sporozoites
This Phase 1 trial will include 16 subjects who will receive the Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum Parasites (GAP3KO) vaccine administered by the bite of approximately 200 infected Anopheles stephensi…
- Trial name
- NCT03168854
- Testing
- Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum parasite (GAP3KO) strain, Malaria challenge
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Study of Malaria Treatment at Phuoc Long Hospital, Binh Phuoc Province, Vietnam
Background: There are worrying signs from Western Cambodia that parasitological responses to artesunate containing treatment regimens for uncomplicated falciparum malaria are slower than elsewhere in the world.
- Trial name
- NCT01165372
- Testing
- Artesunate or dihydroartemisinin-piperaquine
- Where
- Vietnam
- Volunteers
- 166 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Malaria
Optimization of Controlled Human Malarial Infection by Injection of P. Falciparum Sporozoites in Non-Immune Adults
The study is designed to establish the best dose to safely infect healthy individuals with Plasmodium falciparum sporozoites (PfSPZ) by injection.
- Trial name
- NCT01771848
- Testing
- PfSPZ Challenge
- Where
- 2 sites in Spain
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria
Markers of T Cell Suppression: Associations With Malaria Infection and Antimalarial Treatment in Malian Children
Background: The disease malaria can cause very serious health problems. Researchers want to see if malaria affects the way T cells and vaccines work in the body.
- Trial name
- NCT02504918
- Where
- Mali
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Phase2a Primaquine Dose Escalation Study
The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of low single-dose primaquine for gametocidal activity against P.falciparum among adult glucose-6-phosphate dehydrogenase (G6PD)-normal malaria…
- Trial name
- NCT01743820
- Testing
- dihydroartemisinin-piperaquine, 0.125 mg/kg Primaquine, 0.5 mg/kg Primaquine
- Where
- Mali
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Malaria
Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines
This is a Phase Ib trial conducted in Bougouni, Mali to evaluate the safety and immunogenicity of R21/Matrix-M in a single and two vial presentation, with different immunisation schedules, and when co-administered with EPI…
- Trial name
- NCT05155579
- Testing
- R21/Matrix-M - single vial formulation, R21/Matrix-M - two vial formulation, Licensed vaccine - Measles-rubella
- Where
- 2 sites in Mali, United Kingdom
- Volunteers
- 594 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria, Falciparum
Chlorproguanil-Dapsone-Artesunate (CDA) Versus Chlorproguanil-Dapsone (LAPDAP) For Uncomplicated Malaria
CDA is a combination of chlorproguanil, dapsone and artesunate, being developed in a public-private partnership with the Medicines for Malaria Venture (MMV), World Health Organisation (WHO-TDR) and academic partners from the…
- Trial name
- NCT00371735
- Testing
- chlorproguanil-dapsone-artesunate, chlorproguanil-dapsone
- Where
- 7 sites in Burkina Faso, Ghana and 2 more
- Volunteers
- 900 people
- Sponsor
- GlaxoSmithKline
Malaria
Safety and Protective Efficacy of IV Immunization With Cryopreserved PfSPZ Under A/P Chemoprophylaxis
Single center, randomized, placebo-controlled, double-blinded trial using PfSPZ Challenge (NF54) under A/P chemoprophylaxis for immunization and PfSPZ Challenge (NF54) and PfSPZ Challenge (7G8) for repeat CHMI.
- Trial name
- NCT02858817
- Testing
- atovaquone/proguanil 250mg/100mg (A/P), PfSPZ Challenge (NF54), NaCl 0,9%
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.